Top Markets
Coin of the day
Enochian Biosciences, Inc. Enochian Biosciences, Inc.

Enochian Biosciences, Inc.

ENOB
Rang in Aktien #19951
Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to... Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to the research and advancement of novel pharmaceutical and biological agents. Its primary focus lies in developing treatments for a range of human diseases, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza, coronavirus infections, and various cancers. The company's leading investigational products encompass ENOB-HV-01, an autologous therapy aimed at achieving an HIV cure; ENOB-HV-11, a preventative HIV vaccine candidate; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, which targets the HBV polymerase. Beyond these primary programs, Enochian Biosciences' developmental pipeline also features ENOB-DC-11, an off-the-shelf dendritic cell vaccine designed for multiple solid tumors, and ENOB-DC-21, a non-specific vaccine intended for direct intratumoral injection. The company collaborates strategically with prominent research organizations such as The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Founded in 2017, Enochian Biosciences, Inc. operates from its headquarters in Los Angeles, California.
Aktienkurs
$2.60
Zuletzt synchronisiert: 2023-08-29
Marktkapitalisierung
$145.54M
Veränderung (1 Tag)
9.24%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Enochian Biosciences, Inc. (ENOB)

Kategorie

P/B-Verhältnis für Enochian Biosciences, Inc. (ENOB)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Enochian Biosciences, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Enochian Biosciences, Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH